Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of “Buy” by Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has earned an average rating of “Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $19.83.

DCTH has been the topic of a number of research analyst reports. Craig Hallum initiated coverage on shares of Delcath Systems in a research note on Friday, June 28th. They issued a “buy” rating and a $18.00 price target on the stock. HC Wainwright upped their target price on shares of Delcath Systems from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, May 15th. StockNews.com raised shares of Delcath Systems to a “sell” rating in a research note on Wednesday, March 27th. Finally, Stephens initiated coverage on shares of Delcath Systems in a research note on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DCTH. AIGH Capital Management LLC acquired a new position in Delcath Systems during the 4th quarter worth approximately $4,918,000. Vivo Capital LLC boosted its holdings in shares of Delcath Systems by 94.9% in the 1st quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock valued at $7,950,000 after buying an additional 811,555 shares in the last quarter. Worth Venture Partners LLC acquired a new position in shares of Delcath Systems in the 4th quarter valued at $1,224,000. ADAR1 Capital Management LLC acquired a new position in shares of Delcath Systems in the 4th quarter valued at $962,000. Finally, BVF Inc. IL boosted its holdings in shares of Delcath Systems by 23.1% in the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after buying an additional 225,918 shares in the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Price Performance

Shares of DCTH stock opened at $8.16 on Wednesday. The firm’s 50-day moving average is $7.20 and its two-hundred day moving average is $5.43. Delcath Systems has a 12 month low of $2.25 and a 12 month high of $9.18. The company has a market capitalization of $226.77 million, a PE ratio of -3.08 and a beta of 0.64.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Tuesday, May 14th. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $3.70 million. Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. Sell-side analysts forecast that Delcath Systems will post -1.31 EPS for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.